nChroma Bio develops targeted in vivo delivery systems and high-performance genetic cargo to enhance the efficacy of genetic therapies. The company addresses the challenge of inefficient delivery mechanisms that limit the therapeutic potential of genetic medicines.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NMFounders
Product
Problem
Current genetic therapies are limited by inefficient delivery mechanisms, which restrict their therapeutic potential and overall efficacy. This challenge hinders the widespread application of genetic medicines for various diseases.
Solution
nChroma Bio develops targeted in vivo delivery systems and high-performance genetic cargo designed to enhance the effectiveness of genetic therapies. By focusing on improving delivery technologies, nChroma Bio aims to overcome the limitations of existing genetic medicines and unlock their full potential. The company's approach seeks to optimize the delivery of genetic material to specific cells and tissues within the body, thereby maximizing therapeutic impact.
Target Audience
nChroma Bio's primary customers are biotechnology companies and research institutions involved in the development and application of genetic therapies.
Features
- Targeted in vivo delivery systems for precise genetic cargo administration.
- High-performance genetic cargo designed for optimal therapeutic effect.